The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis
Parham Habibzadeh, Mohammad Mofatteh, Saeid Ghavami, Jamshid Roozbeh, The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis, European Journal of Pharmacology, Volume 888, 2020, 173487, ISSN 0014-2999, https://doi.org/10.1016/j.ejphar.2020.17
3 Pages Posted: 15 Jun 2020 Last revised: 21 Aug 2020
Date Written: June 4, 2020
Acute kidney injury (AKI) is an important complication of COVID-19 encompassing a wide range of presentations. SARS-CoV-2 is proposed to cause AKI in the patients through various mechanisms. We are, nevertheless, far from a comprehensive understanding of the underlying pathophysiological mechanisms of the kidney injury in this infection. AKI has been shown to be a marker of disease severity and also a negative prognostic factor for survival. Unfortunately, no effective preventive strategy to decrease the risk of kidney damage in these patients has yet been identified. In this hypothesis, we highlight the potential protective effects of acetazolamide, a carbonic anhydrase inhibitor, in preventing the proximal tubular damage caused by the virus through disrupting the virus-endosome fusion and also interfering with the lysosomal proteases. Our proposed mechanisms could pave the way for further in vitro studies and subsequent clinical trials.
Note: Declaration of Interest: None to declare.
Funding: None to declare
Keywords: COVID-19, SARS-CoV-2, Acute Kidney Injury, Acetazolamide, Carbonic Anhydrases
Suggested Citation: Suggested Citation